Chong Kun Dang Pharmaceutical Corp. Logo

Chong Kun Dang Pharmaceutical Corp.

185750 | KO

Overview

Corporate Details

ISIN(s):
KR7185750007
LEI:
Country:
South Korea
Address:
서울 서대문구 충정로3가 3가 368 종근당빌딩, 서대문구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

No description available.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Regulatory Filings
투자판단관련주요경영사항 (텔미누보정(CKD828) 식품의약품안전처 국내 품목허가 승인)
Korean 7.2 KB
2025-08-22 00:00
Regulatory Filings
투자판단관련주요경영사항 (텔미누보정(CKD828) 식품의약품안전처 국내 품목허가 신청)
Korean 13.5 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 4.9 MB
2025-08-01 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.3 KB
2025-07-24 00:00
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
Korean 15.8 KB
2025-06-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 99.9 KB
2025-06-12 00:00
Regulatory Filings
유형자산취득결정
Korean 7.9 KB
2025-06-12 00:00
Regulatory Filings
풍문또는보도에대한해명(미확정)
Korean 8.0 KB
2025-06-10 00:00
Regulatory Filings
풍문또는보도에대한해명(미확정)
Korean 6.2 KB
2025-06-02 00:00
Governance Information
기업지배구조보고서공시
Korean 1.8 MB
2025-05-22 00:00
Regulatory Filings
기타경영사항(자율공시) (CKD510 기술수출 관련 마일스톤 수령)
Korean 5.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.9 MB
2025-04-30 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.3 KB
2025-04-23 00:00
Regulatory Filings
투자판단관련주요경영사항 (듀비엠폴서방정(CKD383) 식품의약품안전처 국내 품목허가 신청)
Korean 16.9 KB
2025-04-23 00:00
Regulatory Filings
투자판단관련주요경영사항 (듀비엠파정(CKD398) 식품의약품안전처 국내 품목허가 신청)
Korean 16.6 KB

Automate Your Workflow. Get a real-time feed of all Chong Kun Dang Pharmaceutical Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chong Kun Dang Pharmaceutical Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chong Kun Dang Pharmaceutical Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

FARON PHARMACEUTICALS OY Logo
Develops myeloid cell-targeting immunotherapies for solid and hematological cancers.
Finland
FARN
FATE THERAPEUTICS INC Logo
Develops off-the-shelf iPSC cell therapies for cancer and autoimmune diseases.
United States of America
FATE
FENNEC PHARMACEUTICALS INC. Logo
Prevents chemotherapy-induced hearing loss in children with its sole product, PEDMARK®.
United States of America
FENC
FibroBiologics, Inc. Logo
Clinical-stage biotech developing fibroblast cell therapies for chronic diseases.
United States of America
FBLG
FIBROGEN INC Logo
Biopharma developing first-in-class therapies for cancer, anemia, and serious conditions.
United States of America
FGEN
Fine Foods & Pharmaceuticals Ntm Logo
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy
FF
FITLIFE BRANDS, INC. Logo
Provides nutritional supplements for sports nutrition, weight management, and general health.
United States of America
FTLF
Flora Growth Corp. Logo
A diversified firm in pharma distribution, plant-based wellness, and digital assets.
United States of America
FLGC
FluoGuide A/S Logo
Develops fluorescent drugs to guide surgeons for more precise cancer removal and patient outcomes.
Denmark
FLUO
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany
FYB

Talk to a Data Expert

Have a question? We'll get back to you promptly.